{"preliminary_commentary":{"by_channel":{"x_thread":164,"youtube":22,"podcast":22,"x_video":5,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04586231\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-30T00:42:25.226Z","note":"Automated from the 40 newest of 214 indexed sources (Mar 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether the OS findings support a treatment benefit\n- Whether benefit varies by prior immunotherapy regimen\n- How toxicity trade-offs should shape regimen selection\n\nAlso discussed: response durability, real-world benchmarks."},"drugs_tested":[["belzutifan","lenvatinib"]],"indication":"advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy","name":"LITESPARK-011","nct_id":"NCT04586231","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=litespark-011-nct04586231. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Belzutifan 120 mg and lenvatinib 20 mg orally once a day","label":"Belzutifan + Lenvatinib","type":"EXPERIMENTAL"},{"description":"Cabozantinib 60 mg orally once a day","label":"Cabozantinib","type":"ACTIVE_COMPARATOR"}],"collaborators":["Eisai Inc."],"completion_date":{"date":"2027-02-11","type":"ESTIMATED"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":747,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Belzutifan","otherNames":["PT2977","MK-6482","WELIREG™"],"type":"DRUG"},{"name":"Lenvatinib","otherNames":["Lenvima","E7080","MK-7902"],"type":"DRUG"},{"name":"Cabozantinib","otherNames":["Cabometyx","Cometriq","XL184","BMS-907351"],"type":"DRUG"}],"last_update":"2026-05-05","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 34 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 44 months"}],"references":[{"citation":"Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M; LITESPARK-011 Investigators. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet. 2026 Aug 12:S0140-6736(26)01089-5. doi: 10.1016/S0140-6736(26)01089-5. Online ahead of print.","pmid":"42586114","type":"DERIVED"},{"citation":"Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8.","pmid":"36752726","type":"DERIVED"}],"start_date":{"date":"2021-02-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","url":"https://clinicaltrials.gov/study/NCT04586231"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/litespark-011-nct04586231"}